<DOC>
	<DOCNO>NCT01573494</DOCNO>
	<brief_summary>Circulating tumor cell ( CTC ) subject increase interest clinical oncology prognostic factor predictor therapeutic response . The detection CTC immunomagnetic method prove reliability usefulness monitoring breast cancer , colon prostate metastatic immunomagnetic detection system ( CellSearch , Veridex LLC ) approve FDA indication . However , date reliable method detect CTCs melanoma ( CMC ) . Studies base PCR amplification mRNA reverse specific melanoma disappointing . Recently , new detection system CMC immunomagnetic present ( CellSearch , Veridex LLC , United States ) . This system advantage combine immunomagnetic selection step step identify immunofluorescence . A preclinical study serial dilution melanoma cell show encouraging result . The investigator propose prospective study CellSearch system patient melanoma . Primary objective : To determine effect treatment number circulate melanoma cell patient metastatic melanoma . Secondary objective : - determine percentage patient metastatic melanoma melanoma cell circulate - seek relationship number circulate melanoma cell prognosis patient metastatic melanoma - seek relationship change number circulate melanoma cell / treatment tumor response patient metastatic melanoma</brief_summary>
	<brief_title>Study Circulating Tumor Cells Before After Treatment Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Patients &gt; = 18 year Patients advance melanoma stage IIIC ( unresectable ) stage IV Patient treat respond chemotherapy chemotherapy session last &gt; 1 month Patients sign informed consent Patients present socioeconomic , psychological , familial geographical allow proper understand information leaflet protocol regular monitoring department dermatology Patients life expectancy great 3 month Patients melanoma measurable RECIST version 1.1 Patients venous good venipuncture Patients contraindication treatment chemotherapy V600E BRAF inhibitor ipilimumab condition concomitant heavy may interfere treatment metastatic melanoma Pregnant woman nurse People vulnerable detainee , adult guardianship curatorship , minor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Circulating Tumor Cells</keyword>
</DOC>